Calcium Channel Fingered In Ebola’s Infection Pathway | March 2, 2015 Issue - Vol. 93 Issue 9 | Chemical & Engineering News
Volume 93 Issue 9 | p. 8 | News of The Week
Issue Date: March 2, 2015 | Web Date: February 26, 2015

Calcium Channel Fingered In Ebola’s Infection Pathway

Virology: Two-pore channel 2 could provide a druggable target for treating or preventing ebola virus
Department: Science & Technology
News Channels: Biological SCENE
Keywords: ebola, tetrandrine, two pore channel, TPC2

A critical step in the path the Ebola virus takes to infect host cells has been elucidated. Scientists found the virus requires a specific calcium channel to release its viral genome into a host cell. The researchers could block this process with tetrandrine, a drug used in China to treat high blood pressure, suggesting a possible Ebola virus therapy.

Robert A. Davey, of the Texas Biomedical Research Institute, in San Antonio, had long suspected that calcium signaling channels were crucial to the Ebola virus’s infection process. Now, he and an international team of researchers have identified two-pore channel 2 (TPC2) as key (Science 2015, DOI: 10.1126/science.1258758).

TPC2 channels are found in a cell’s endosomes—the cellular sorting compartments that break down proteins for recycling. These calcium channels control the way endosomes move through cells. Ebola viruses pop up in endosomes after host cells engulf them whole.

The researchers found that mice genetically engineered to not have TPC2 evaded Ebola infection. In normal mice and in cell culture, the small-molecule TPC2 blocker tetrandrine stopped virus trafficking. Davey tells C&EN that his team is currently looking at tetrandrine derivatives to see if they can also halt the virus.

Darryl Falzarano, an infectious disease expert at Canada’s Vaccine & Infectious Disease Organization-International Disease Centre, who studies Ebola virus, says the finding is exciting from a basic research perspective. “Ebola clearly undergoes a complex series of steps in its entry pathway, and defining the cellular requirements for this process may one day lead to novel targets for intervention,” he says.

Falzarano cautions, however, that the finding won’t lead to immediate new Ebola therapies. Tetrandrine isn’t approved for use in humans outside China and faces a long slog through the regulatory process. Also, he suspects it might be better as a prophylactic Ebola treatment than one for people already infected with the virus. Tetrandrine or a derivative eventually may be part of a combination Ebola therapy, Falzarano says, “but this would be a considerable time in the future.”

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society
Comments
H L Sam Queen (March 9, 2015 5:23 PM)
This exciting news for those of us who look at such findings from a health model-based perspective. Certain calcium channels are well known to become overly active in some people with high blood pressure, a fact that is subject to the 55/45% balance between bound and free, ionized calcium. As the level of bound calcium drops, an excess of free, unbound calcium occurs, prompting some loss of sensitivity of control of calcium channels, which has somewhat accounted for high blood pressure in some people. Since this is most often preceded either by a loss of phosphorous or albumin, or a drop in the acid/base balance, it stands to reason that control of these data points has a sooner chance of being employed as a preventative step in the battle to curtail Ebola than to wait upon the approval of a drug that would block the correct calcium channels.

Leave A Comment

*Required to comment